Jacqueline Deloumeaux

Prof. Jacqueline Deloumeaux

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in The Lancet
Verified
Journal Article
Open access
CAClaudia Allemani
Claudia Allemani
TMTomohiro Matsuda
Tomohiro Matsuda
VCVeronica Di Carlo
Veronica Di Carlo
RHRhea Harewood
Rhea Harewood
MMMelissa Matz
Melissa Matz
CLC Lewis
C Lewis
In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. CONCORD-3 includes individual records for 37·5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights. For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89·5% in Australia and 90·2% in the USA, but international differences remain very wide, with levels as low as 66·1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68·9%), colon (71·8%), and rectum (71·1%); in Japan for oesophageal cancer (36·0%); and in Taiwan for liver cancer (27·9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59·9% in South Korea, 52·1% in Taiwan, and 49·6% in China), and for both lymphoid malignancies (52·5%, 50·5%, and 38·3%) and myeloid malignancies (45·9%, 33·4%, and 24·8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49·8% in Ecuador to 95·2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28·9% in Brazil to nearly 80% in Sweden and Denmark). The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer. American Cancer Society; Centers for Disease Control and Prevention; Swiss Re; Swiss Cancer Research foundation; Swiss Cancer League; Institut National du Cancer; La Ligue Contre le Cancer; Rossy Family Foundation; US National Cancer Institute; and the Susan G Komen Foundation.

1 July 2019 in Bulletin du Cancer
Verified
Journal Article
Closed access
ACAnne Cowppli-Bony
Anne Cowppli-Bony
MCMarc Colonna
Marc Colonna
KLKarine Ligier
Karine Ligier
VJValérie Jooste
Valérie Jooste
GDGautier Defossez
Gautier Defossez
AWAnne-Sophie Woronoff
Anne-Sophie Woronoff

1 October 2002 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
LFLydia Foucan
Lydia Foucan
JHJim Hanley
Jim Hanley
JDJacqueline Deloumeaux
Jacqueline Deloumeaux
SSSamy Suissa
Samy Suissa

1 October 1999 in AIDS
Verified
Journal Article
Closed access
JTJean-Michel Tassie
Jean-Michel Tassie
JGJacques Gasnault
Jacques Gasnault
MBMichèle Bentata
Michèle Bentata
JDJacqueline Deloumeaux
Jacqueline Deloumeaux
FBFrançois Boué
François Boué
DCDominique Costagliola
Dominique Costagliola
To estimate the change in survival of patients with AIDS-related progressive multifocal leukoencephalopathy (PML), in relation to the introduction of protease inhibitors (PI). The French Hospital Database on HIV (FHDH) is a prospective cohort of 70 224 HIV-infected subjects. This study included the patients diagnosed with PML between 1 July 1995 and 30 June 1997. PML diagnosis was both presumptive and confirmed. We compared the survival probability according to the diagnosis period (period 1 or 2, before or after introduction of PI in France on 1 April 1996). Cox's model was used to calculate the relative hazards of death according to the antiretroviral regimen. The study included 246 patients, 109 diagnosed during period 1 and 137 during period 2. In all, 131 patients received an antiretroviral combination that included PI. By 31 December 1997, a total of 131 deaths had been reported. The probability of survival at 6 months for patients from period 2 was nearly twice as high as for patients from period 1 (60.5 versus 34.5%). In comparison with patients receiving no treatment, the risk of death in patients on combination therapy not including PI was reduced by 38% [relative hazard (RH) 0.62, 95% confidence interval (CI) (0.41; 0.95), P = 0.026] and in patients on combination therapy with PI, by 63% [RH 0.37, 95% CI (0.22; 0.64), P = 0.0004]. This study of a large cohort of patients diagnosed with PML (n = 246), provides evidence that a combination antiretroviral regimen, especially one including PI, confers marked survival benefits.

1 February 2010 in Emerging Infectious Diseases
Verified
Journal Article
Open access
CHCécile Herrmann-Storck
Cécile Herrmann-Storck
MLMagalie Saint Louis
Magalie Saint Louis
TFTania Foucand
Tania Foucand
ILIsabelle Lamaury
Isabelle Lamaury
JDJacqueline Deloumeaux
Jacqueline Deloumeaux
MCMuriel Cornet
Muriel Cornet
We evaluated prognostic factors for leptospirosis in 168 consecutive hospitalized patients in Guadeloupe. Factors independently associated with severity included chronic hypertension or chronic alcoholism, late initiation of antibacterial therapy, abnormal chest auscultation results, icterus, oligoanuria, disorders of consciousness, elevated aspartate aminotransferase levels, hyperamylasemia, and Leptospira interrogans serovar Icterohemorrhagiae.

1 December 2011 in Diabetes & Metabolism
Verified
Journal Article
Closed access
FVF.-L. Vélayoudom-Céphise
F.-L. Vélayoudom-Céphise
LLLaurent Larifla
Laurent Larifla
JDJ.-P. Donnet
J.-P. Donnet
SMS. Maimaitiming
S. Maimaitiming
JDJacqueline Deloumeaux
Jacqueline Deloumeaux
LFL. Foucan
L. Foucan